Opinion|Videos|January 29, 2025
Best Practices in Switching PBC Therapies
Panelists discuss how clinicians may transition patients to newer agents due to factors such as inadequate biochemical response, tolerability issues (particularly pruritus), or patient preference, while carefully considering the need for washout periods based on each drug's pharmacokinetics and mechanism of action.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some reasons why clinicians may consider a transition from obeticholic acid to seladelpar or elafibranor for PBC?
- Given the different mechanisms of action of obeticholic acid, seladelpar, and elafibranor, what factors should be considered in determining the need for a washout period between treatments vs direct transition?
Advertisement
Related to this article
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
5